Phase II Randomized Study of Figitumumab Plus Docetaxel and Docetaxel Alone With Crossover for Metastatic Castration-Resistant Prostate Cancer

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-13-1869

Related search